Abattis Bioceuticals Corp
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cann… Read more
Abattis Bioceuticals Corp (ATTBF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2019: 0.369x
Based on the latest financial reports, Abattis Bioceuticals Corp (ATTBF) has a cash flow conversion efficiency ratio of 0.369x as of September 2019.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.93 Million) by net assets ($10.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Abattis Bioceuticals Corp - Cash Flow Conversion Efficiency Trend (2008–2019)
This chart illustrates how Abattis Bioceuticals Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Abattis Bioceuticals Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abattis Bioceuticals Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vista Land & Lifescapes Inc Preferred Series 2B
PSE:VLL2B
|
N/A |
|
Green Giant Inc.
NASDAQ:GGEI
|
-0.269x |
|
G RENT SPA
F:7F3
|
N/A |
|
Uravi Defence and Technology Limited
NSE:URAVIDEF
|
N/A |
|
Nextgen
TA:NXGN
|
0.111x |
|
450940
KQ:450940
|
N/A |
|
PURPOSE MARIJ.OPP. TR.UTS
F:43V
|
N/A |
|
Nabors Energy Transition Corp. II Warrant
NASDAQ:NETDW
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Abattis Bioceuticals Corp (2008–2019)
The table below shows the annual cash flow conversion efficiency of Abattis Bioceuticals Corp from 2008 to 2019.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2019-09-30 | $10.67 Million | $9.41 Million | 0.882x | +218.25% |
| 2018-09-30 | $11.10 Million | $-8.28 Million | -0.746x | +52.91% |
| 2017-09-30 | $771.48K | $-1.22 Million | -1.584x | +54.67% |
| 2016-09-30 | $209.78K | $-733.21K | -3.495x | +8.64% |
| 2015-09-30 | $476.68K | $-1.82 Million | -3.825x | -742.37% |
| 2014-09-30 | $4.64 Million | $-2.11 Million | -0.454x | -10.11% |
| 2013-09-30 | $558.02K | $-230.15K | -0.412x | -1.95% |
| 2012-09-30 | $623.47K | $-252.22K | -0.405x | +50.85% |
| 2011-09-30 | $590.60K | $-486.08K | -0.823x | +3.62% |
| 2010-09-30 | $380.01K | $-324.51K | -0.854x | -488.25% |
| 2009-09-30 | $584.12K | $-84.80K | -0.145x | -12891.05% |
| 2008-09-30 | $-55.51K | $-63.00 | 0.001x | -- |